MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A Phase 2, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults with Isolated Cervical Dystonia

J. Jankovic, C. Oh, Y. Liu, C. Comella (Irvine, USA)

Meeting: 2023 International Congress

Abstract Number: 778

Keywords: Botulinum toxin: Clinical applications: dystonia, Dystonia: Clinical features, Dystonia: Treatment

Category: Dystonia: Clinical Trials and Therapy

Objective: To evaluate the safety and the efficacy of ABP-450 (prabotulinumtoxinA) in patients with cervical dystonia (CD).

Background: ABP-450 (prabotulinumtoxinA) is a new 900kDA botulinumtoxinA.

Method: Adult subjects with moderate to severe CD with a baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score of ≥20 were invited to participate in a randomized double blinded, multi-center, placebo-controlled study of ABP-450 at doses of 150 U, 250 U and 350 U. The study drug was administered to the affected muscles and the subjects were evaluated every 4 weeks following the injection. At least 6 weeks post injection, the subjects were invited to discontinue their participation in the blinded study and enroll in the open label extension if there was minimal response or loss of efficacy in the opinion of the investigators and the subjects. The primary efficacy outcome was the change in TWSTRS from baseline to week 4. The secondary outcomes included the duration of effect, patient global impression of change (PGI-C) and clinical global impression of change (CGI-C) at week 4.

Results: Of the 70 subjects screened, 61 were randomized, 59 were dosed, and 57 were included in the efficacy analysis. Treatment effect (vs. placebo) based on mean change from baseline in TWSTRS total score at week 4 was -10.44 (p=0.0070) for 150U, -7.71 (p=0.0406) for 250U, and -6.35 (p=0.0864) for 350U. There was no statistically significant difference between the three doses. CGI-C and PGI-C were statistically significantly improved over placebo at week 4 in all three ABP-450 groups and the median duration of treatment effect were ≥20.  Treatment-related adverse events, reported in 16 subjects (36%), included dysphagia (11.1%), neck weakness (6.7%), and headache (4.4%).

Conclusion: ABP-450 at doses of 150U and 250U demonstrated statistically significant and clinically meaningful efficacy with relatively sustained benefit. ABP-450 appeared to be generally safe and well tolerated.

To cite this abstract in AMA style:

J. Jankovic, C. Oh, Y. Liu, C. Comella. A Phase 2, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults with Isolated Cervical Dystonia [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/a-phase-2-double-blinded-placebo-controlled-trial-to-evaluate-the-efficacy-and-safety-of-abp-450-prabotulinumtoxina-in-adults-with-isolated-cervical-dystonia/. Accessed June 23, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-phase-2-double-blinded-placebo-controlled-trial-to-evaluate-the-efficacy-and-safety-of-abp-450-prabotulinumtoxina-in-adults-with-isolated-cervical-dystonia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Life expectancy with and without Parkinson’s disease in the general population
    • The hardest symptoms that bother patients with Parkinson's disease
    • Patients with Essential Tremor Live Longer than their Relatives
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley